Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin

Haematologica

Volumn 95, Issue 3, 2010, Pages 505-508

  Ashby, Damien R ^a   Gale, Daniel P ^a,b   Busbridge, Mark ^a   Murphy, Kevin G ^a   Duncan, Neill D ^a   Cairns, Tom D ^a   Taube, David H ^a   Bloom, Stephen R ^a   Tam, Frederick W K ^a   Chapman, Richard ^a   Maxwell, Patrick H ^b   Choi, Peter ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anemia of chronic disease; Erythropoietin; Ferritin; GDF15; Hepcidin; Iron

Indexed keywords

ERYTHROPOIETIN; FERRITIN; GROWTH DIFFERENTIATION FACTOR 15; HEPCIDIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; ERYTHROPOIESIS; FEMALE; HEMATOCRIT; HUMAN; IRON BALANCE; IRON KINETICS; IRON STORAGE; MALE; NORMAL HUMAN; PHLEBOTOMY;

ADULT; ANTIMICROBIAL CATIONIC PEPTIDES; BONE MARROW; ERYTHROPOIETIN; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INJECTIONS, SUBCUTANEOUS; IRON; MALE; RECEPTORS, TRANSFERRIN; TRANSFERRIN;

EID: 77949707023     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013136     Document Type: Article

References (28)

1. Huff RL, Elmlinger PJ, Garcia JF, Oda JM, Cockrell MC, Lawrence JH. Ferrokinetics in normal persons and in patients having various erythropoietic disorders. J Clin Invest. 1951;30(12):1512-26.
2. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037-44.
3. Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood. 2005;106(2):746-8.
4. Kemna E, Pickkers P, Nemeth E, van der HH, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005;106(5):1864-6.
5. Ganz T. Molecular control of iron transport. J Am Soc Nephrol. 2007;18(2):394-400.
6. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-3.
7. Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood. 2005;106(2):746-8.
8. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008; 112(10):4292-7.
9. Kemna EH, Kartikasari AE, van Tits LJ, Pickkers P, Tjalsma H, Swinkels DW. Regulation of hepcidin: insights from biochemical analyses on human serum samples. Blood Cells Mol Dis. 2008;40(3):339-46.
10. Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003;361(9358):669-73.
11. Nemeth E, Roetto A, Garozzo G, Ganz T, Camaschella C. Hepcidin is decreased in TFR2 hemochromatosis. Blood. 2005; 105(4):1803-6.
12. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108(12):3730-5.
13. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006; 55(6):667-74.
14. Kattamis A, Papassotiriou I, Palaiologou D, Apostolakou F, Galani A, Ladis V, et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica. 2006;91(6):809-12.
15. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J, et al. Hepcidin in iron overload disorders. Blood. 2005;105(10):4103-5.
16. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976-81.
17. Robach P, Recalcati S, Girelli D, Gelfi C, Aachmann-Andersen NJ, Thomsen JJ, et al. Alterations of systemic and muscle iron metabolism in human subjects treated with low dose recombinant erythropoietin. Blood. 2009;113(26):6707-15.
18. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976-81.
19. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75(9):976-81.
20. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S. Suppression of hepcidin during anemia requires erythropoietic activity. Blood. 2006;108(12):3730-5.
21. Spivak JL, Pham T, Isaacs M, Hankins WD. Erythropoietin is both a mitogen and a survival factor. Blood. 1991;77(6):1228-33.
22. Krzyzanski W, Perez-Ruixo JJ. An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects. Pharm Res. 2007;24(4):758-72.
23. Lok CN, Loh TT. Regulation of transferrin function and expression: review and update. Biol Signals Recept. 1998;7(3):157-78.
24. Cazzola M, Beguin Y, Bergamaschi G, Guarnone R, Cerani P, Barella S, et al. Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis. Br J Haematol. 1999;106(3):752-5.
25. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096-101.
26. Weizer-Stern O, Adamsky K, Amariglio N, Levin C, Koren A, Breuer W, et al. Down-regulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera. Br J Haematol. 2006;135(1):129-38.
27. Lakhal S, Talbot NP, Crosby A, Stoepker C, Townsend AR, Robbins PA, et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood. 2009; 113(7):1555-63.
28. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003; 101(7):2461-3.